The normal HCT trial re-revisited: What were the actual findings?

Kidney International

Volumn 82, Issue 2, 2012, Pages 242-

  Besarab, Anatole ^a   Bolton, W Kline ^a   Nissenson, Allen R ^a   Schwab, Steven J ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADVERSE OUTCOME; ANEMIA; CHRONIC KIDNEY DISEASE; DRUG TARGETING; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LETTER; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL TIME; THROMBOSIS;

EID: 84863313967     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.204     Document Type: Letter

References (3)

1. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012; 82: 235-241.
2. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med 1998; 339: 584-590.
3. Goodkin DA. The normal hematocrit cardiac trial revisited. Semin Dial 2009; 22: 495-502.